Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY Prostate Cancer Blood Test

Aeterna Zentaris Inc. today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY®, the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc.

Read more…